高级检索
当前位置: 首页 > 详情页

The clinical efficacy of transfusion of cytokine-induced killer cells combined with chemotherapy and XiaoJi decoction in patients with stage IIIB/IV Non-small cell lung cancer

文献详情

资源类型:
WOS体系:

收录情况: ◇ CPCI(ISTP)

机构: [1]Guangdong Provincial Hospital of Chinese Medicine [2]Guangzhou University of Chinese Medicine, Guangzhou City, China
出处:
ISSN:

关键词: Non-small cell Lung cancer Cytokine-induced killer cells Adjuvant immunotherapy Xiaoji decoction Effectiveness

摘要:
Objective: To evaluate the clinical efficacy and safety of cytokine-induced killer (CIK) cells immunotherapy in combination with platinum chemotherapy and Xiaoji decoction in patients with advanced stage non-small cell lung cancer (NSCLC). Methods: Patients with advanced stage NSCLC were randomly assigned to Group A (platinum chemotherapy plus xiaoji decoction) and Group B (platinum chemotherapy plus xiaoji decoction and CIK cell transfusion). Progression free survival (PFS), disease control rate (DCR), overall response rate (ORR) , Karnofsky score (KPS), host cellular immune response and treatment related side effects were assessed. Results: Patients in Group B had significantly longer PFS than those in Group A. The overall response rate (ORR) and the disease control rate (DCR) showed no statistical difference between the Group B and Group A The level of CD3(+), CD4(+) were significantly higher after treatment, The level of CD3(+) in Group A was significant lower after treatment. There were no immediate adverse reactions between the 2 groups. Conclusion: This study suggest that CIK cells immunotherapy combined with platinum chemotherapy and Xiaoji decoction may become an effective strategy to improve the survival and prolong the PFS of patients with advanced stage NSCLC.

基金:
语种:
WOS:
第一作者:
第一作者机构: [1]Guangdong Provincial Hospital of Chinese Medicine
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:2018 今日访问量:0 总访问量:645 更新日期:2024-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 广东省中医院 技术支持:重庆聚合科技有限公司 地址:广州市越秀区大德路111号